Clinical Pipeline

Learn more about our pipeline

Trials for Market Approval

Download PPT

Optimized Background Regimen (OBR)

Pre-Clinical (GLP)

OTB-658

Institute of Materia Medica, CAMS & PUMC

FNDR 20364

National Centre of Oceanic and Antarctic Research (NCAOR), Gao, India

FNDR-20081

Foundation for Neglected Disease Research

TB47

Guangzhou Institute of Respiratory Medicine Company Limited, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China

GSK839

GlaxoSmithKline

S-004992

Shionogi & Co., Ltd

CLB073

Bill & Melinda Gates Medical Research Institute

MBX-4888A

Microbiotix, Inc.

Faropenem WBA

SPRINT-TB (National University of Singapore)

Gyrase B Inhibitor

Vertex Pharmaceuticals, Incorporated

Quinolone TBK-613

TB Alliance

Phase 1

TBD09 (MK7762)

Bill & Melinda Gates Medical Research Institute, Merck & Co., Inc., NIAID, NIH, DHHS

Safety, Tolerability, Pharmacokinetics (PK), and Food Effect of MK-7762 in Healthy Adults

GSK-286

GlaxoSmithKline, TB Drug Accelerator, Bill & Melinda Gates Foundation

Phase 1 Safety, Tolerability and Pharmacokinetics of GSK2556286

TBAJ-587, Diarylquinoline

TB Alliance, ERA4TB (European Regimen Accelerator for Tuberculosis), University of Auckland, Merck & Co., Inc.

TBI-223

TB Alliance, Institute of Materia Medica

TBI-223 Phase 1 MAD

Safety, Tolerability, Pharmacokinetics (PK), and Food Effect of MK-7762 in Healthy Adults

Bill & Melinda Gates Medical Research Institute, Merck & Co., Inc.

Macozinone (MCZ, PBTZ-169)

iM4TB - Innovative Medicines for Tuberculosis, Bill & Melinda Gates Foundation

TBI-166

Institute of Materia Medica, CAMS & PUMC

Contezolid (MRX-4/MRX-1)

MicuRx Pharmaceuticals, Inc.

TBA-354

TB Alliance

Phase 2

DECISION

PRESCIENT Trial

Brigham and Women's Hospital

PAN-TB XBQS Trial

Bill & Melinda Gates Medical Research Institute

PanACEA - STEP2C-01

Radboud University

CRUSH-TB

CDC TBTC

DRAMATIC Trial

Boston University

NC-009 Trial

TB Alliance

Quabodepistat (OPC-167832)

Otsuka Pharmaceutical Development & Commercialization, Inc.

Phase 2b/c. 4-month Regimen of OPC-167832, Delamanid and Bedaquiline for DS Pulmonary TB

PAN-TB XBQS Trial

Sanfetrinem

GlaxoSmithKline, Bill & Melinda Gates Foundation

Phase 2: EBA, Safety and Tolerability of Sanfetrinem Cilexetil

Sutezolid

Sequella, Inc, TB Alliance

Sutezolid Dose-finding and Combination Evaluation (SUDOCU)

PAN-TB XBQS Trial

BTZ-043

University of Munich, Hans-Knöll Institute, Jena, German Center for Infection Research (DZIF), European and Developing Countries Clinical Trials Partnership (EDCTP), Radboud University

DECISION

Rifapentine

CDC TBTC, Sanofi

CLO-FAST

PredictTB

NIAID, NIH, DHHS, Bill & Melinda Gates Foundation, EDCTP

Clofazimine

Novartis

endTB-Q

DRAMATIC Trial

PRESCIENT Trial

CLO-FAST